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OBJECTIVES: This study models the costs of mRCC treatment for selected targeted 
agents (AIs and mTORs) in 18 US community oncology clinics using medical resource 
utilization data collected from patient medical charts. METHODS: Data were 
abstracted for 297 non-trial mRCC patients ≥18 years, receiving sunitinib (n = 131), 
sorafenib (n = 119), bevacizumab (n = 19), or temsirolimus (n = 28) as ﬁrst-line tar-
geted agent. Per-patient-per-month (PPPM) costs (2009 USD) were estimated for 
targeted agents, intravenous administration, other drugs, procedures, hospitalizations, 
and treatment of adverse events (AEs; including drugs, procedures, hospitalizations, 
and ofﬁce visits for AE treatment). Drug costs were estimated using Average Wholesale 
Price, procedure costs were based on US private insurance reimbursement, hospitaliza-
tion costs were based on HCUP National Inpatient Sample discharge diagnosis charges 
and published average cost-to-charge ratio. RESULTS: Median treatment duration 
was 5.9 (sunitinib), 5.5 (sorafenib), 6.7 (bevacizumab), and 2.8 (temsirolimus) 
months. Total PPPM costs (mean ± SE) were $9,417.35 ± 670.78 (sunitinib), 
$7,992.48 ± 682.29 (sorafenib), $14,770.48 ± 1,393.25 (bevacizumab), and 
$11,493.39 ± 1,256.53 (temsirolimus). AI drug costs comprised 64% (sunitinib, 
sorafenib), 79% (bevacizumab), and 55% (temsirolimus) of total PPPM cost. AE 
treatment costs PPPM were $1,972.62 ± 560.86 (sunitinib, 21% of total PPPM costs), 
$1,302.58 ± 559.54 (sorafenib, 16%), $425.25 ± 265.69 (bevacizumab, 3%), and 
$1,810.85 ± 627.63 (temsirolimus, 16%). Given the median treatment durations, total 
costs over course of ﬁrst-line AI were estimated as $55,562 (sunitinib), $43,959 
(sorafenib), $98,962 (bevacizumab), and $32,181 (temsirolimus), including intrave-
nous administration costs of $2,497 (bevacizumab) and $2,111 (temsirolimus). CON-
CLUSIONS: Targeted agent drug cost was a major contributor to the total health care 
PPPM costs in patients with mRCC, followed by AE treatment costs. While AEs may 
be largely related to tolerability for sunitinib and sorafenib, AE treatment cost was as 
high as 21% and 16% of total cost. This study is limited by small sample sizes for 
bevacizumab and temsirolimus.
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OBJECTIVES: A prior retrospective chart review study described treatment patterns 
and drug-related adverse events (AEs) for mRCC pts treated with sunitinib or 
sorafenib in a tertiary center in Italy (ECCO-ESMO, 2009). This study modeled the 
costs of these treatments and AEs. METHODS: Medical records were reviewed for 
non-trial pts with mRCC, ≥18 years old, treated with sunitinib (n = 85) or sorafenib 
(n = 60) after January 1, 2005. Data collected included patients’ health care resource 
utilization. Cost data for the Italian health care system were obtained from various 
sources including published literature and publicly available information from the 
Italian government. The components of the total per-patient-per-month (PPPM) costs 
(in 2008 Euro) included costs of MKI drugs, diagnostic and therapeutic procedures, 
hospitalizations, management of MKI-treatment-related adverse events (AEs), and 
prescription drugs for conditions other than mRCC. RESULTS: Median treatment 
duration was 6.6 months (sunitinib) and 5.8 months (sorafenib). Total costs PPPM 
were (mean ± SD) 33868.97 ± 710.49 (sunitinib) and 33448.01 ± 1,178.96 (sorafenib). 
MKI drug costs, equal to 33566.33 ± 481.36 (sunitinib) and 33110.85 ± 622.25 
(sorafenib), were the largest contributor to total PPPM costs, followed by AE treat-
ment costs of 3107.89 ± 405.42 (sunitinib) and 3222.16 ± 991.18 (sorafenib), and 
procedure costs of 375.48 ± 72.15 (sunitinib) and 379.94 (sorafenib). Given the 
median treatment durations, the total cost over the course of ﬁrst-line MKI treatment 
is estimated to be 325,535 for sunitinib and 319,998 for sorafenib, with the cost of 
AE treatment amounting to 3712 for sunitinib and 31,289 for sorafenib. CONCLU-
SIONS: This study used health care resource utilization data from a real clinic setting 
and costs from published literature to estimate costs associated with MKI treatment 
in patients with mRCC in Italy. MKI drug cost was the major contributor to total 
PPPM cost, followed by the cost associated with treatment of AEs. This retrospective 
study is limited by small sample sizes from a single center.
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RETROSPECTIVE US CLAIMS DATABASE ANALYSIS OF THE COST OF 
SEQUENCING OF SORAFENIB AND SUNITINIB IN THE TREATMENT OF 
PATIENTS WITH RENAL CELL CARCINOMA (RCC)
Moyneur E1, Dorff T2, Barghout V3, Meyers S3, Hu J2, Quinn D2
1StatLog Consulting Inc., L’Ange-Gardien, QC, Canada, 2USC Keck School of Medicine, Los 
Angeles, CA, USA, 3Bayer HealthCare Pharmaceuticals Inc, Wayne, NJ, USA
OBJECTIVES: An earlier analysis in ﬁrst-line treatment of RCC patients with similar 
baseline characteristics demonstrated signiﬁcantly greater costs with sunitinib than 
sorafenib. Evidence from case series supports the use of sorafenib or sunitinib sequen-
tial therapy for RCC disease control. Direct medical costs associated with each 
sequence were quantiﬁed. METHODS: Patients in MarketScan®, a U.S. health care 
claims database covering all U.S. census regions and >18 million lives annually from 
2002–2009, were retrospectively analyzed. Inclusion: ≥2 RCC claims (ICD9 189.0; 
198.0), continuous health care coverage, ≥1 switch (sorafenib to sunitinib; sunitinib 
to sorafenib), > 180 days’ coverage before switch date. Observation period: ﬁrst-line 
therapy ≤12 months before switch, ending ≤12 months after switch. Second-line 
therapy (switch) ended with next dispensing of sorafenib, sunitinib, bevacizumab, or 
temsirolimus; disenrollment; death; or study end (March 31, 2009). A person-time 
approach was used. Limitations include physician coding and lack of disease staging. 
RESULTS: At time of switch, no signiﬁcant differences in baseline characteristics 
existed between groups (sunitinib, n = 153; sorafenib, n = 119), except longer enrol-
ment in health plan in patients who received sorafenib ﬁrst (12.4 vs 8.8 months; 
P < 0.0001) and higher prevalence of anemia in patients who received sunitinib ﬁrst 
(52.9% vs 32.8%, P < 0.001). Univariate incremental total per member per month 
(PMPM) medical costs in those who received sunitinib ﬁrst were $1639 (P = 0.0003) 
more than those treated with sorafenib ﬁrst, largely due to signiﬁcantly higher outpa-
tient costs PMPM in those who received sunitinib ﬁrst ($1252; P < 0.0001). Overall, 
this represents an annual cost savings of $19,668 in RCC patients initially treated 
with sorafenib. CONCLUSIONS: In this retrospective US claims database analysis, 
we observed statistically signiﬁcantly lower costs in RCC patients initially treated with 
sorafenib, the difference mainly attributable to outpatient costs. Future cost analyses 
should be incorporated into prospective trials of RCC sequencing.
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OBJECTIVES: To compare the safety proﬁle of nilotinib, observed in a large study 
of CML patients in a clinical practice setting to the product information of nilotinib 
and dasatinib. METHODS: Adult patients with imatinib resistant or intolerant Ph+ 
CML in chronic phase (CP), accelerated phase (AP), or blast crisis (BC) were recruited 
in this phase IIIb, open label, multi-center study. Patients received nilotinib 400 mg 
BID and were not permitted to dose escalate. Follow-up treatment in managing the 
hematological and non-hematological adverse event (AE), were recorded. Health care 
resource utilization was estimated by constructing six-month marginal cost increase 
in patients who received follow-up care for the management of AE. Cost data were 
obtained from MedStat MarketScan database that contained over 5000 CML patients. 
RESULTS: A total of 207 patients (172 CP pts, 15 AP pts, and 20 BC pts) were 
enrolled in the study between June 2006–October 2008. The percentage of patients 
with grade 3/4 hematological AEs suspected of being study drug-related in CP and AP 
were thrombocytopenia (12%, 20%), neutropenia (9%, 27%), and anemia (1.2%, 
13%). The most frequent non-hematologic AEs (all grades) included rash, headache, 
nausea, and fatigue. The percentage of patients requiring additional therapy for the 
reported hematological AEs was less than 50% in most cases. Total medical costs 
associated with managing the AEs, estimated from MedStat cost data, for both hema-
tological and non-hematological AEs were $6314 over a 6-month period. Medical 
costs associated with managing hematological AEs made up the majority of these costs. 
The estimated costs from this study were signiﬁcantly lower compared to the estimated 
burden of the AEs in the product information for nilotinib or dasatinib ($9,730 and 
$12,372, respectively). CONCLUSIONS: Nilotinib related AE costs observed in this 
large clinical practice setting study compare favorably to the estimated costs from 
product information from nilotinib and dasatinib.
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OBJECTIVES: To describe cost associated to the treatment of different stages of non 
Hodgkin lymphoma at the Social Security Mexican Institute (IMSS) from the health 
care payer’s perspective. METHODS: A cost study was made. Resource use and cost 
data were obtained from hospital (second and tertiary levels) records of 70 treated 
patients from July 2008 to February 2009 using the following inclusion criteria: 
patients older than 16 years with non-Hodgkin lymphoma histological diagnosis who 
accepted to be included in the protocol through informed consent. Although, patients 
excluded were those who showed a second malignant neoplasm or incomplete infor-
mation. We calculate mean,standard deviation (SD), median, 25 percentil and 75 
percentil for each clinical stage and statistical differences were estimated through 
ANOVA tests, p value <0.05 was considered signiﬁcant to show differences. RESULTS: 
The median total cost per patient was US $3150.19 (US $2482.67 to US $5300.16), 
the mean cost per chemotherapy was US $3595.96 (SD: US $693.27), mean cost to 
